Diversified Trust Co Buys 2,600 Shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM)

Diversified Trust Co lifted its stake in shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM) by 24.6% during the first quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 13,173 shares of the medical device company’s stock after purchasing an additional 2,600 shares during the quarter. Diversified Trust Co’s holdings in Tandem Diabetes Care were worth $466,000 as of its most recent SEC filing.

A number of other institutional investors have also added to or reduced their stakes in the stock. MCF Advisors LLC boosted its holdings in Tandem Diabetes Care by 79.3% in the 1st quarter. MCF Advisors LLC now owns 1,006 shares of the medical device company’s stock valued at $36,000 after purchasing an additional 445 shares during the period. Van ECK Associates Corp boosted its stake in Tandem Diabetes Care by 8.6% during the fourth quarter. Van ECK Associates Corp now owns 5,900 shares of the medical device company’s stock valued at $175,000 after buying an additional 467 shares during the period. RiverPark Advisors LLC purchased a new position in Tandem Diabetes Care during the fourth quarter worth about $27,000. PNC Financial Services Group Inc. increased its stake in Tandem Diabetes Care by 51.7% in the 3rd quarter. PNC Financial Services Group Inc. now owns 3,226 shares of the medical device company’s stock worth $67,000 after acquiring an additional 1,099 shares during the last quarter. Finally, GAMMA Investing LLC raised its holdings in shares of Tandem Diabetes Care by 55.7% in the 1st quarter. GAMMA Investing LLC now owns 3,845 shares of the medical device company’s stock valued at $136,000 after acquiring an additional 1,375 shares in the last quarter.

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on TNDM shares. Barclays lifted their target price on shares of Tandem Diabetes Care from $39.00 to $55.00 and gave the company an “overweight” rating in a research report on Monday, May 6th. SVB Leerink upgraded shares of Tandem Diabetes Care from a “market perform” rating to an “outperform” rating and upped their target price for the stock from $34.00 to $45.00 in a research report on Thursday, April 25th. Lake Street Capital raised their price target on Tandem Diabetes Care from $60.00 to $75.00 and gave the company a “buy” rating in a research report on Wednesday, May 22nd. Wells Fargo & Company raised Tandem Diabetes Care from an “equal weight” rating to an “overweight” rating and lifted their price target for the stock from $21.00 to $45.00 in a research note on Monday, April 29th. Finally, Piper Sandler reiterated an “overweight” rating and set a $50.00 price objective (up from $35.00) on shares of Tandem Diabetes Care in a research report on Friday, May 3rd. Two equities research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $51.25.

Tandem Diabetes Care Stock Up 1.7 %

Shares of Tandem Diabetes Care stock opened at $39.82 on Thursday. The company’s 50 day moving average price is $44.85 and its 200-day moving average price is $34.17. Tandem Diabetes Care, Inc. has a 52-week low of $13.82 and a 52-week high of $53.69. The company has a debt-to-equity ratio of 1.43, a quick ratio of 3.01 and a current ratio of 3.81. The stock has a market capitalization of $2.57 billion, a price-to-earnings ratio of -18.35 and a beta of 1.28.

Tandem Diabetes Care (NASDAQ:TNDM) last released its quarterly earnings data on Thursday, May 2nd. The medical device company reported ($0.63) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.80) by $0.17. The firm had revenue of $191.67 million for the quarter, compared to analysts’ expectations of $173.06 million. Tandem Diabetes Care had a negative net margin of 18.37% and a negative return on equity of 34.38%. Equities research analysts forecast that Tandem Diabetes Care, Inc. will post -1.71 EPS for the current year.

Insider Activity at Tandem Diabetes Care

In other Tandem Diabetes Care news, Director Dick Allen sold 5,000 shares of the stock in a transaction that occurred on Thursday, May 30th. The stock was sold at an average price of $51.68, for a total value of $258,400.00. Following the completion of the sale, the director now owns 24,396 shares in the company, valued at approximately $1,260,785.28. The transaction was disclosed in a document filed with the SEC, which is available at this link. 2.20% of the stock is owned by company insiders.

Tandem Diabetes Care Company Profile

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.